ERBB2 and cancer: One study found that selectively targeting p95HER2 positive cells with CD3-p95HER2 BsAb (CD3-p95HER2 describes the two targeted antigens in this BsAb) was cytotoxic to cancer cells expressing p95HER2 and was nonlethal to HER2+/p95HER2- tissue in vitro and in vivo [65].